Apr 1 2014
Merrimack Pharmaceuticals, Inc. today announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol* as an MRI imaging agent prior to MM-398 investigational treatment.
Additional preclinical presentations describe the relationship between ferumoxytol and MM-398 tumor uptake and activity, as well as exploring the mechanistic basis of MM-398 activity across multiple tumor models. Data will be presented in four poster sessions.
Poster Sessions
- Session Title: Clinical Trials
Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI
Monday, April 7, 2014 8:00 AM - 12:00 PM
Hall A-E, Poster Section 38
- Session Title: Tumor Biology 24
Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)
Monday, April 7, 2014 1:00 PM - 5:00 PM
Hall A-E, Poster Section 7
- Session Title: Tumor Biology 38
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression
Tuesday, April 8, 2014 1:00 PM - 5:00 PM
Hall A-E, Poster Section 5
- Session Title: Experimental and Molecular Therapeutics 37
Evaluating the pharmacodynamics and pharmacokinetic effects of MM-398, a nanoliposomal irinotecan (nal-IRI), in subcutaneous xenograft tumor models of human squamous cell carcinoma and small cell lung cancers
Tuesday, April 8, 2014 1:00 PM - 5:00 PM
Hall A-E, Poster Section 35
About MM-398
MM-398 is a nanoliposomal formulation of irinotecan. MM-398 is being evaluated in several clinical trials including a Phase 3 study in metastatic pancreatic cancer, a Phase 2 study in patients with metastatic colorectal cancer and a Phase 1 cross indication translational study. MM-398 is not approved for any indication by the U.S. Food and Drug Administration or any other regulatory agency. Under a 2011 agreement with PharmaEngine, Inc. (Taipei, Taiwan), Merrimack consolidated the worldwide development and commercialization rights to MM-398, with the exception of commercialization rights in Taiwan which are held by PharmaEngine, Inc.
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at merrimackpharma.com.
Source: http://www.merrimackpharma.com/